Deconstructing a medication regimen

Journal of Psychiatric Practice

Volumn 14, Issue 2, 2008, Pages 114-118

  Preskorn, Sheldon H ^a,b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

^b University of Montreal   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZATROPINE; CARBAMAZEPINE; FLUOXETINE; LITHIUM; NORFLUOXETINE; RANITIDINE; RISPERIDONE; VALPROIC ACID;

AKATHISIA; ARTICLE; BIPOLAR DISORDER; CASE REPORT; COMMUNITY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DYSPEPSIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HOSPITAL; HUMAN; LABORATORY; MEDICAL INFORMATION; OUTPATIENT DEPARTMENT; PARENT; PARKINSONISM; PSYCHIATRIST;

ADOLESCENT; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BENZTROPINE; BIOTRANSFORMATION; BIPOLAR DISORDER; CARBAMAZEPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; FLUOXETINE; HUMANS; LITHIUM CARBONATE; METABOLIC CLEARANCE RATE; RANITIDINE; RISPERIDONE; STUPOR; VALPROIC ACID;

EID: 41149139538     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pra.0000314318.87168.9e     Document Type: Article

References (29)

1. Preskorn SH. Mania in a case of polypsychopharmacology: Pharmacodynamic and pharmacokinetic considerations: Do you believe in magic? J Psychiatr Pract 2007;13:178-83.
2. Preskorn SH. The rationale for and clinical implications of dose-response curves and The polypharmacology section. Two series of columns published in J P Psychiatr Pract (available at www.preskorn.com, accessed March 5, 2008).
3. Beasley CM, Jr, Bosomworth JC, Wernicke JF, et al. Fluoxetine: Relationships among dose, response, adverse events, and plasma concentrations in the treatment of depression. Psychopharmacol Bull 1990;26:18-24.
4. Norman TR, Gupta RK, Burrows GD, et al. Relationship between antidepressant response and plasma concentrations of fluoxetine and norfluoxetine. Int Clin Psychopharmacol 1993;8:25-9.
5. Harvey AT, Preskorn SH. Fluoxetine pharmacokinetics and effect on CYP2C19 in young and elderly volunteers. J Clin Psychopharmacol 2001;21:161-6.
6. Darby JK, Pasta DJ, Rlfand L, et al. Risperidone dose and blood level variability: Accumulation effects and interindividual and intraindividual variability in the nonresponder patient in the clinical practice setting. J Clin Psychopharmacol 1997;17:478-84.
7. Aravagiri M, Marder SR, Wirshing D, et al. Plasma concentrations of risperidone and its 9-hydroxy metabolite and their relationship to dose in schizophrenic patients: Simultaneous determination by a high performance liquid chromatography with electrochemical detection. Pharmacopsychiatry 1998;31:102-9.
8. Yasui-Furukori N, Kondo T, Suzuki A, et al. Comparison of prolactin concentrations between haloperidol and risperidone treatments in the same female patients with schizophrenia. Psychopharmacology (Berl) 2002;1621:63-6.
9. Wang L, Yu L, Zhang AP, et al. Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia. J Psychopharmacol 2007;21:837-42.
10. Chicharro AV, de Marinis AJ, Kanner AM. The measurement of ammonia blood levels in patients taking valproic acid: Looking for problems where they do not exist? Epilepsy Behav 2007;11:361-6.
11. Dealberto MJ. Valproate-induced hyperammonaemic encephalopathy: Review of 14 cases in the psychiatric setting. Int Clin Psychopharmacol 2007;22:330-7.
12. Suppes T, Baldessarini RJ, Faedda GL, et al. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry 1991;48:1082-8.
13. Baldessarini RJ, Tondo L, Viguera AC, et al. Discontinuing lithium maintenance treatment in bipolar disorders: Risks and implications. Bipolar Disord 1999;1:17-24.
14. Perlis RH, Sachs GS, Lafer B, et al. Effect of abrupt change from standard to low serum levels of lithium: A reanalysis of double-blind lithium maintenance data. Am J Psychiatry 2002;159:1155-9.
15. Biel MG, Peselow E, Mulcare L, et al. Continuation versus discontinuation of lithium in recurrent bipolar illness: A naturalistic study. Bipolar Disord 2007;9:435-42.
16. Ono S, Mihara K, Suzuki A, et al. Significant pharmacokinetic interaction between risperidone and carbamazepine: Its relationship with CYP2D6 genotypes. Psychopharmacology (Berl) 2002;162:50-4.
17. Preskorn SH, Flockhart DA. 2006 guide to psychiatric drug interactions. Prim Psychiatry 2006;13:35-64.
18. Shad MU, Preskorn SH. Antidepressants. In: Levy RH, Thummel KE, Trager WF, eds. Metabolic drug interactions. Philadelphia: Lippincott, Williams & Wilkins; 2000:563-77.
19. Hemeryck A, Belpaire FM. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: An update. Curr Drug Metab 2002;3:13-37.
20. Preskorn SH. Multiple medication use presenting as Parkinson's dementia complex: A message from Titanic. 2008;14:45-54.
21. Roth A, Akyol S, Nelson JC. Delirium associated with the combination of a neuroleptic, an SSRI, and benztropine. J Clin Psychiatry 1994;55:492-5.
22. Spina E, Avenoso A, Scordo MG, et al. Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: A clinically relevant pharmacokinetic drug interaction. J Clin Psychopharmacol 2002;22:419-23.
23. de Leon J, Susce M T, Pan RM, et al. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 2005;66:15-27.
24. Preskorn SH. Neuroleptic malignant syndrome resulting from a complex drug-drug interaction: "I don't see 'em!" J Psychiatr Pract 2007;13:328-333.
25. Ghaemi SN, Hsu DJ, Soldani F, et al. Antidepressants in bipolar disorder: The case for caution. Bipolar Disord 2003;5: 421-33.
26. Amsterdam JD, Shults J. Fluoxetine monotherapy of bipolar type II and bipolar NOS major depression: A double-blind, placebo-substitution, continuation study. Int Clin Psychopharmacol 2005;20:257-64.
27. Levy RH, Koch KM. Drug interactions with valproic acid. Drugs 1982;24:543-56.
28. Spina E, Pisani F, Perucca E. Clinically significant pharmacokinetic drug interactions with carbamazepine: An update. Clin Pharmacokinet 1996;31:198-214.
29. Preskorn SH, Lacey RL. Polypharmacy: When is it rational? J Psychiatr Pract 2007;13:97-105.